文献速递白血病

儿童B细胞急性淋巴细胞白血病风险分类的细化:DFCI ALL联盟05-001方案结果

Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
PubMed 文献 · Blood Adv · 2018-01-01

DFCI ALL联盟05-001方案在678例新诊断儿童及青少年B-ALL中测试新的风险分层系统。根据年龄、白细胞计数及中枢神经系统状态分为标危和高危,缓解后依据诱导后微小残留病(MRD)≥10^-3和/或不良细胞遗传学(KMT2A重排或亚二倍体)重新分为极高危并接受强化治疗。全组5年无事件生存率为87%,IKZF1缺失为预后不良的独立预测因素。

要点

  • 全组678例5年无事件生存率87%(95%CI 84-89),总生存率93%(95%CI 90-94)。
  • 标危、高危、极高危5年无病生存率分别为94%、84%、79%。
  • IKZF1缺失见于62/385例(16%),与较差5年无事件生存率相关(63% vs 88%,P<.001)。

核心结论

  • DFCI 05-001方案的风险分层治疗使B-ALL患者获得良好结局,包括具有极高危特征者。
  • IKZF1缺失是预后不良的独立预测因素。

研究设计与样本

  • Dana-Farber癌症研究所(DFCI)ALL联盟05-001方案为在儿童及青少年新诊断急性淋巴细胞白血病中测试新风险分层系统的研究。
  • 2005年至2011年共纳入678例1至18岁费城染色体阴性B-ALL患者,651例达完全缓解,648例获得最终风险分组。
  • 入组时依据年龄、白细胞计数及中枢神经系统状态分为标危或高危;缓解后对诱导后MRD≥10^-3和/或不良细胞遗传学(KMT2A重排或亚二倍体)者重新分为极高危并接受强化治疗。
  • IKZF1缺失状态通过多重连接依赖探针扩增法进行回顾性评估。
  • 该试验注册于www.clinicaltrials.gov,编号#NCT00400946。

主要发现

  • 全部678例患者5年无事件生存率为87%(95%CI 84-89),总生存率为93%(95%CI 90-94)。
  • 标危组(N=407)5年无病生存率为94%(95%CI 91-96),高危组(N=176)为84%(95%CI 77-88),极高危组(N=65)为79%(95%CI 67-87)。
  • IKZF1缺失见于62/385例(16%)受检患者,与较差5年无事件生存率相关(63%;95%CI 49%-74% vs 88%;95%CI 84%-91%;P<.001),且5年累积复发率更高,包括在低MRD者中(24% vs 8%,P=.001)。
  • 多变量分析中,年龄≥15岁、白细胞≥50×10^9/L、IKZF1缺失及MRD≥10^-4均与较差结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05-001 tested a new risk stratification system in children and adolescents with newly diagnosed acute lymphoblastic leukemia (ALL). At study entry, B-ALL patients were classified as standard risk (SR) or high risk (HR) based on age, white blood cell (WBC) count, and central nervous system status. After achieving complete remission (CR), patients with high end-induction minimal residual disease (MRD) (≥10-3 by polymerase chain reaction analysis of patient-specific antigen receptor rearrangements) and/or adverse cytogenetics (KMT2A rearrangement or hypodiploidy) were reclassified as very high risk (VHR) and received intensified therapy. IKZF1 deletion status was retrospectively evaluated by multiplex ligation-dependent probe amplification. Between 2005 and 2011, 678 Philadelphia chromosome-negative B-ALL patients aged 1 to 18 years enrolled; 651 achieved CR and 648 received a final risk group. Among all 678 patients, 5-year event-free survival (EFS) was 87% (95% confidence interval [CI], 84-89) and overall survival 93% (95% CI, 90-94). Five-year disease-free survival of SR patients (N = 407) was 94% (95% CI, 91-96), HR (N = 176) was 84% (95% CI, 77-88), and VHR (N = 65) was 79% (95% CI, 67-87). IKZF1 deletion was present in 62 of 385 (16%) assessed patients and was associated with inferior 5-year EFS (63%; 95% CI, 49%-74% vs 88%; 95% CI, 84%-91%; P < .001), and higher 5-year cumulative incidence of relapse, including among those with low MRD (24% vs 8%, P = .001). In multivariable analysis, age ≥15 years, WBC ≥50 × 109/L, IKZF1 deletion, and MRD ≥10-4 was each associated with inferior outcome. In conclusion, risk-stratified therapy on DFCI 05-001 resulted in favorable outcomes for B-ALL patients, including those with VHR features. IKZF1 deletion was an independent predictor of inferior outcome. This trial was registered at www.clinicaltrials.gov as #NCT00400946.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vrooman LM, Blonquist TM, Harris MH, et al. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018. PMID: 29941458. doi:10.1182/bloodadvances.2018016584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。